Compare
AbbVie vs United Therapeutics (ABBV vs UTHR)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and United Therapeutics (UTHR) +25.6%; so far this year the figures are +27.5% and +15.3%.
AbbVie is the larger company by market value, about 21.5 times the size of United Therapeutics.
On trailing earnings, ABBV trades at 50.1 times and UTHR at 21.2 times.
Revenue grew +10.7% at ABBV and +1.9% at UTHR over the last year.
ABBV yields 2.38%. UTHR pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | UTHR | |
|---|---|---|
| Price | $291.31 | $562.02 |
| 1-day | +1.07% | -0.65% |
| YTD | +27.49% | +15.35% |
| 1 year | +34.39% | +25.61% |
| 3 years | +104.47% | +150.81% |
| Market cap | $514.9B | $23.9B |
| P/E | 50.1 | 21.2 |
| P/S | 7.80 | 7.51 |
| P/B | — | 3.81 |
| Revenue growth | +10.70% | +1.90% |
| EPS growth | +340.20% | +0.30% |
| Gross margin % | 73.7 | 86.3 |
| Net margin % | 15.7 | 38.6 |
| ROE % | — | 19.6 |
| Debt / equity | — | 0.00 |
| FCF yield % | 3.7 | 3.6 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.37 |
| RSI (14) | 59.7 | 48.9 |
| Technical rating |